Recent trends in epidemiology of dyslipidemias in India
TLDR
There is low awareness, treatment and control of hypercholesterolemia in India, and over a 20-year period total cholesterol, LDL cholesterol and triglyceride levels have increased among urban populations.Abstract:
Dyslipidemia is the most important atherosclerotic risk factor. Review of population based studies in India shows increasing mean total cholesterol levels. Recent studies have reported that high cholesterol is present in 25-30% of urban and 15-20% rural subjects. This prevalence is lower than high-income countries. The most common dyslipidemia in India are borderline high LDL cholesterol, low HDL cholesterol and high triglycerides. Studies have reported that over a 20-year period total cholesterol, LDL cholesterol and triglyceride levels have increased among urban populations. Case-control studies have reported that there is significant association of coronary events with raised apolipoproteinB, total cholesterol, LDL cholesterol and non-HDL cholesterol and inverse association with high apolipoproteinA and HDL cholesterol. Prevalence of suspected familial hypercholesterolemia in urban subjects varies from 1:125 to 1:450. Only limited studies exist regarding lipid abnormalities in children. There is low awareness, treatment and control of hypercholesterolemia in India.read more
Citations
More filters
Journal ArticleDOI
Hypertension: The most important non communicable disease risk factor in India.
Rajeev Gupta,Denis Xavier +1 more
TL;DR: It is estimated that better hypertension control can prevent 400–500,000 premature deaths in India and the importance of high rates of hypertension control for achieving target of 1/3 reduction in non-communicable disease mortality by 2030 is highlighted.
Journal ArticleDOI
A Special Report on Changing Trends in Preventive Stroke/Cardiovascular Risk Assessment Via B-Mode Ultrasonography.
Ankush D Jamthikar,Deep Gupta,Narendra N. Khanna,Tadashi Araki,Luca Saba,Andrew N. Nicolaides,Aditya Sharma,Tomaz Omerzu,Harman S. Suri,Ajay Gupta,Sophie Mavrogeni,Monika Turk,John R. Laird,Athanasios Protogerou,Petros P. Sfikakis,George D. Kitas,Vijay Viswanathan,Gyan Pareek,Martin Miner,Jasjit S. Suri +19 more
TL;DR: Fusion of image-based features with conventional cardiovascular risk factors can lead to more accurate CVD/stroke risk stratification and the ability to handle multiple sources of information in big data framework using artificial intelligence-based paradigms is likely to be the future in preventive CVD-stroke risk assessment.
Journal ArticleDOI
Association Between Blood Heavy Metal Concentrations and Dyslipidemia in the Elderly
Xingmeng Zhu,Yong Fan,Jie Sheng,Ling Gu,Qi Tao,Rui Huang,Kaiyong Liu,Linsheng Yang,Guimei Chen,Hongjuan Cao,Kaichun Li,Fangbiao Tao,Sufang Wang +12 more
TL;DR: It was found that the combined Exposure of aluminum, cobalt, and vanadium was the protective factor of non-dyslipidemia, while the combined exposure of cadmium, strontium, and lead was the risk factor of dys Lipidemia.
Journal ArticleDOI
Prevalence of dyslipidemia among the diabetic patients in southern Bangladesh: A cross-sectional study.
Hrishov Das,Sujan Banik +1 more
TL;DR: The prevalence of dyslipidemia in Bangladesh is significantly high, which indicates the urgency of lifestyle intervention strategies to prevent and manage this important health problem and risk factor.
Journal ArticleDOI
Statins and SARS-CoV-2 disease: Current concepts and possible benefits.
TL;DR: Early observations suggest beneficial effect of statin use on the clinical outcomes in COVID-19 and prospective randomized studies as well as well-designed laboratory studies are required to confirm these observations and to elucidate the mechanisms of such benefits, if proven.
References
More filters
Journal ArticleDOI
Major lipids, apolipoproteins, and risk of vascular disease
E Di Angelantonio,Nadeem Sarwar,P Perry,Stephen Kaptoge,Kausik K. Ray,Alexander J. Thompson,Angela M. Wood,Sarah Lewington,Naveed Sattar,Chris J. Packard,Rory Collins,Simon G. Thompson,John Danesh +12 more
TL;DR: Lid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride.
Journal ArticleDOI
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.
Sarah Lewington,Gary Whitlock,Robert Clarke,Paul Sherliker,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Richard Peto,Rory Collins +8 more
TL;DR: There is conclusive evidence from randomised trials that statins substantially reduce not only coronary event rates but also total stroke rates in patients with a wide range of ages and blood pressures.
Journal ArticleDOI
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
TL;DR: Estimates of the associations of major lipids and apolipoproteins in relation to coronary heart disease (CHD) and ischemic stroke are produced, incorporating adjustment for confounding caused by other risk factors and correction for regression dilution.
Journal ArticleDOI
Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials
Jordan Fulcher,Rachel O'Connell,Merryn Voysey,Jonathan Emberson,L Blackwell,Borislava Mihaylova,John Simes,Rory Collins,Adrienne Kirby,Helen M. Colhoun,Eugene Braunwald,J La Rosa,Terje R. Pedersen,Andrew Tonkin,Barry R. Davis,Peter Sleight,MariaGrazia Franzosi,Colin Baigent,Anthony C Keech +18 more
TL;DR: In men and women at an equivalent risk of cardiovascular disease, statin therapy is of similar effectiveness for the prevention of major vascular events.
Journal ArticleDOI
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
Salim Yusuf,Shofiqul Islam,Clara K Chow,Sumathy Rangarajan,Gilles R. Dagenais,Rafael Diaz,Rajeev Gupta,Roya Kelishadi,Romaina Iqbal,Alvaro Avezum,Annamarie Kruger,Raman Kutty,Fernando Lanas,Liu Lisheng,Li Wei,Patricio Lopez-Jaramillo,Aytekin Oguz,Omar Rahman,H Swidan,Khalid Yusoff,Witold Zatonski,Annika Rosengren,Koon K. Teo +22 more
TL;DR: Overall, few individuals with cardiovascular disease took antiplatelet drugs, β blockers, ACE inhibitors or ARBs, or statins, and use was highest in high-income countries and lowest in low- Income countries, with greatest variation in poorest countries.